Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: Results from the Erectile Dysfunction Observational Study

International Journal of Clinical Practice

Volumn 61, Issue 11, 2007, Pages 1850-1862

  Hatzichristou, D ^a   Haro, J M ^b   Martin Morales, A ^c   Von Keitz, A ^d   Riley, A ^e   Bertsch, J ^f   Belger, M ^g   Wolka, A M ^g   Beardsworth, A ^g  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Esplugues de Llobregat ^*  (Spain)

^c HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^d Urology Practice   (Germany)

^e UNIVERSITY OF CENTRAL LANCASHIRE   (United Kingdom)

^f HOSPITAL CLÍNIC   (Spain)

^g ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TADALAFIL; VARDENAFIL;

ADULT; ARTICLE; COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG SUBSTITUTION; ERECTILE DYSFUNCTION; FOLLOW UP; HEALTH CARE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; CARBOLINES; COHORT STUDIES; ERECTILE DYSFUNCTION; FOLLOW-UP STUDIES; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PROSPECTIVE STUDIES; PURINES; QUESTIONNAIRES; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; SULFONES; TIME FACTORS; TREATMENT OUTCOME; TRIAZINES;

EID: 35348910121     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01560.x     Document Type: Article

References (41)

1. World Population Prospects: The 1996 Revision. New York : United Nations, 1997.
2. Feldman HA, Goldstein I, Hatzichristou DG et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994 151 : 54 61.
3. Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999 84 : 50 6.
4. Wespes E, Amar E, Hatzichristou D et al. EAU guidelines on erectile dysfunction: an update. Eur Urol 2006 49 : 806 15.
5. Hatzimouratidis K, Hatzichristou D. Phosphodiesterase type 5 inhibitors: the day after. Eur Urol 2007 51 : 75 88.
6. Brock GB, McMahon CG, Chen KK et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002 168 : 1332 6.
7. Hellstrom WJ, Gittelman M, Karlin G et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002 23 : 763 71.
8. Goldstein I, Lue TF, Padma-Nathan H et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998 338 : 1397 404.
9. Althof SE. When an erection alone is not enough: biopsychosocial obstacles to lovemaking. Int J Impot Res 2002 14 : S99 S104.
10. Rosen RC, Fisher WA, Eardley I et al. The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin 2004 20 : 607 17.
11. Leiblum SR. After sildenafil: bridging the gap between pharmacologic treatment and satisfying sexual relationships. J Clin Psychiatry 2002 63 : 17 22.
12. McCullough AR, Barada JH, Fawzy A et al. Achieving treatment optimization with sildenafil citrate (Viagra) in patients with erectile dysfunction. Urology 2002 60 : 28 38.
13. Atiemo HO, Szostak MJ, Sklar GN. Salvage of sildenafil failures referred from primary care physicians. J Urol 2003 170 : 2356 8.
14. Hatzichristou D, Moysidis K, Apostolidis A et al. Sildenafil failures may be due to inadequate patient instructions and follow-up: a study on 100 non-responders. Eur Urol 2005 47 : 518 22.
15. Hatzimouratidis K, Moysidis K, Bekos A et al. Treatment strategy for 'non-responders' to tadalafil and vardenafil: a real-life study. Eur Urol 2006 50 : 126 32.
16. Haro JM, Beardsworth A, Casariego J et al. Treatment-seeking behavior of erectile dysfunction patients in Europe: results of the Erectile Dysfunction Observational Study. J Sex Med 2006 3 : 530 40.
17. Martin-Morales A, Haro JM, Beardsworth A et al. Therapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: results from the Erectile Dysfunction Observational Study (EDOS). Eur Urol 2007 51 : 541 50.
18. Riley A, Beardsworth A, Kontodimas S et al. Sexual intercourse frequency in men presenting for treatment of erectile dysfunction: results from the pan-European Erectile Dysfunction Observational Study. J Sex Marital Ther 2007 33 : 3 18.
19. Rosen RC, Riley A, Wagner G et al. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997 49 : 822 30.
20. Swindle R, Cameron A, Rosen R. A 15-item short form of the psychological and interpersonal relationship scales. Int J Impot Res 2006 18 : 82 8.
21. Fagelman E, Fagelman A, Shabsigh R. Efficacy, safety, and use of sildenafil in urologic practice. Urology 2001 57 : 1141 4.
22. Souverein PC, Egberts AC, Meuleman EJ et al. Incidence and determinants of sildenafil (dis)continuation: the Dutch cohort of sildenafil users. Int J Impot Res 2002 14 : 259 65.
23. Gonzalgo ML, Brotzman M, Trock BJ et al. Clinical efficacy of sildenafil citrate and predictors of long-term response. J Urol 2003 170 : 503 6.
24. Son H, Park K, Kim SW, Paick JS. Reasons for discontinuation of sildenafil citrate after successful restoration of erectile function. Asian J Androl 2006 6 : 117 20.
25. Arver S, Perimenis P, Heidler H et al. Factors influencing continuation of tadalafil treatment for erectile dysfunction at 6 months: results from the DETECT study. J Sex Med 2007 4 (Suppl. 2 137.
26. Verheyden B, Roumeguère T, Bitton A et al. Effectiveness and patient satisfaction with 6 months' tadalafil treatment: results from the DETECT study. J Sex Med 2007 4 (Suppl. 2 161.
27. Brock G. Tadalafil for the treatment of erectile dysfunction. Urol Rev 2002 168 : 1332 6.
28. Porst H, Padma-Nathan H, Giuliano F et al. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 h after dosing: a randomized, controlled trial. Urology 2003 62 : 121 5.
29. Viagra (sildenafil citrate) Prescribing Information. http://pfizer.com/ pfizer/download/uspi_viagra.pdf (accessed August 2007).
30. Levitra (vardenafil HCl) Prescribing Information. http://www.univgraph. com/bayer/inserts/levitra.pdf (accessed August 2007).
31. Moncada I, Jara J, Subira D et al. Efficacy of sildenafil citrate at 12 h after dosing: re-exploring the therapeutic window. Eur Urol 2004 46 : 357 60.
32. Porst H, Sharlip ID, Hatzichristou D et al. Extended duration of efficacy of vardenafil when taken 8 h before intercourse: a randomized, double-blind, placebo-controlled study. Eur Urol 2006 50 : 1086 94.
33. Forgue ST, Patterson BE, Bedding AW et al. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol 2006 61 : 280 8.
34. Nichols DJ, Muirhead GJ, Harness JA. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects, and dose proportionality. Br J Clin Pharmacol 2002 53 : 5S 12S.
35. Rajagopalan P, Mazzu A, Xia C et al. Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. J Clin Pharmacol 2003 43 : 260 7.
36. Hanson-Divers C, Jackson SE, Lue TF et al. Health outcomes variables important to patients in the treatment of erectile dysfunction. J Urol 1998 159 : 1541 7.
37. Carson CC, Rajfer J, Eardley I et al. The efficacy and safety of tadalafil: an update. BJU Int 2004 93 : 1276 81.
38. Skoumal R, Chen J, Kula K et al. Efficacy and treatment satisfaction with on-demand tadalafil (Cialis) in men with erectile dysfunction. Eur Urol 2004 43 : 362 9.
39. Padma-Nathan H, Montorsi F, Giuliano F et al. Vardenafil restores erectile function to normal range in men with erectile dysfunction. J Sex Med 2007 4 : 152 61.
40. Kell PD, Hvidsten K, Morant SV et al. Factors that predict changing the type of phosphodiesterase type 5 inhibitor medication among men in the UK. BJU Int 2007 99 : 860 3.
41. Lee J, Pommerville P, Brock G et al. Physician-rated patient preference and patient- and partner-rated preference for tadalafil or sildenafil citrate: results from the Canadian 'Treatment for Erectile Dysfunction' observational study. BJU Int 2006 98 : 623 9.